Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
protein_peptide
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03434262CT.gov SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | — | Completed | — | — | — |
NCT02444546CT.gov Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primitive Neuroectodermal Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | St. Jude Children's Research Hospital | P1 | CCC · 52 |
| Tasadenoturev | DNAtrix, Inc. | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab | DNAtrix, Inc. | P2 | B |
| Genistein | University of Virginia | P2 | CCC |
| Belzutifan | José Claudio Casali da Rocha | P2 | CCC |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | CCC |
| Pralsetinib, Trans- | Hoffmann-La Roche | P1/2 | CCC |
| Interleukin-12 | Second Affiliated Hospital, School of Medicine, Zhejiang University | P1/2 | CCC |
+13 more in the Primitive Neuroectodermal Tumor cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Primitive Neuroectodermal Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-primitive-neuroectodermal-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →